Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
about
CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvementThe effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancerGenetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genesStereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmiasEffect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine.Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.
P2860
Q28239473-C5291CEC-B1AE-4508-9119-D7F42FA06EC3Q34357697-9927C634-71A9-4B25-A7A9-14B6C9C03D33Q34358477-94A871A5-7EAD-4040-B9D1-7B5DC6A1AEEAQ34397040-82AF82BC-D43B-41D0-9559-1F1D7CCA774AQ34398346-FD178812-A959-4F2C-A5C9-2B07FD2F74FDQ34400605-22D45D44-EB5D-4A54-B9E4-5AF740B2013EQ34403471-AA8E1263-2881-47D4-8D8D-9426C4AE995CQ35825489-2281EC70-16E1-4621-9ABF-650FB7D7FE97Q36055046-4229CD0B-8924-4A81-9E50-5CF03336E172Q41940518-5F338EA6-5FD3-42D8-B37A-1BE804B724B1Q42229235-0F1D34D1-637F-47E1-8A2D-65A5156072B7Q43222504-60395C59-1F55-4DD3-9546-01D120809D5EQ43483244-18075619-D594-4982-BF6B-822CCDC993DDQ45040972-7C5376E8-F179-45C8-B967-8966DDF7FDC9Q50940024-2A8CAF17-7F3A-4706-8C0D-DCE6FBE43DD3Q51579932-9F69B14A-60B4-440E-BE4B-A8BAE636C795
P2860
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
description
1986 nî lūn-bûn
@nan
1986 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
@ast
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
@en
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
@nl
type
label
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
@ast
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
@en
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
@nl
prefLabel
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
@ast
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
@en
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
@nl
P2860
P1476
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1986.TB05251.X
P407
P577
1986-08-01T00:00:00Z